FDC Ltd

₹ 352 0.10%

18 Sep - close price

About

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.^[1]

Key Points

Revenue Breakup FY25^[1]
Formulations: 92%,
Bulk Drugs : 6%,
Profit share - Formulation: 2%

Website BSE NSE

Market Cap ₹ 5,739 Cr.
Current Price ₹ 352
High / Low ₹ 495 / 313
Stock P/E 18.4
Book Value ₹ 153
Dividend Yield 1.42 %
ROCE 15.5 %
ROE 11.4 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 19.4%

Cons

The company has delivered a poor sales growth of 9.95% over past five years.
Company has a low return on equity of 12.4% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	530	480	452	454	624	505	459	482	642	462	458	564	655
	410	401	370	396	482	433	413	429	501	427	408	453	512
Operating Profit	120	79	82	58	142	72	46	53	141	35	50	112	143
OPM %	23%	16%	18%	13%	23%	14%	10%	11%	22%	8%	11%	20%	22%
	30	27	25	21	28	35	19	31	36	21	1	47	47
Interest	1	1	1	1	1	1	1	1	1	1	1	2	1
Depreciation	10	10	10	10	11	14	13	16	15	15	15	14	15
Profit before tax	139	95	96	67	158	92	50	68	161	39	35	143	174
Tax %	22%	24%	19%	28%	27%	20%	28%	29%	24%	25%	22%	25%	24%
	109	72	78	48	115	74	36	48	122	29	27	107	132
EPS in Rs	6.54	4.42	4.81	2.96	7.06	4.54	2.24	2.96	7.51	1.81	1.67	6.58	8.11
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	877	986	1,008	1,061	1,074	1,328	1,323	1,516	1,777	1,916	2,070	2,126	2,139
	680	759	766	835	854	1,033	999	1,269	1,522	1,578	1,750	1,774	1,800
Operating Profit	197	227	242	225	220	295	324	247	255	338	320	352	339
OPM %	22%	23%	24%	21%	20%	22%	25%	16%	14%	18%	15%	17%	16%
	44	40	44	45	51	71	97	79	54	103	106	90	117
Interest	2	1	1	1	1	3	3	3	4	4	4	5	5
Depreciation	38	34	35	35	33	37	38	37	39	40	54	59	59
Profit before tax	201	232	250	234	236	325	380	285	266	398	368	378	392
Tax %	27%	27%	25%	28%	27%	24%	23%	23%	24%	23%	26%	24%
	146	169	187	168	172	247	294	220	201	307	274	286	296
EPS in Rs	8.20	9.50	10.52	9.65	9.84	14.43	17.45	13.01	12.11	18.87	16.81	17.56	18.17
Dividend Payout %	28%	24%	21%	0%	0%	6%	0%	0%	0%	0%	30%	28%

Compounded Sales Growth
10 Years:	8%
5 Years:	10%
3 Years:	6%
TTM:	2%

Compounded Profit Growth
10 Years:	5%
5 Years:	0%
3 Years:	11%
TTM:	11%

Stock Price CAGR
10 Years:	5%
5 Years:	0%
3 Years:	-2%
1 Year:	-28%

Return on Equity
10 Years:	13%
5 Years:	12%
3 Years:	12%
Last Year:	11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	18	18	18	18	18	17	17	17	17	16	16	16
Reserves	912	1,059	1,246	1,245	1,416	1,525	1,705	1,932	1,964	2,081	2,271	2,476
	1	1	1	1	1	15	14	31	28	20	21	15
	209	181	195	224	192	249	207	274	327	341	402	404
Total Liabilities	1,140	1,259	1,459	1,488	1,625	1,806	1,943	2,254	2,335	2,459	2,710	2,912
	381	671	674	670	678	670	685	701	695	676	848	994
CWIP	29	20	6	13	12	24	19	104	198	261	136	96
Investments	496	325	491	472	585	665	790	886	806	850	1,050	1,070
	234	243	287	333	349	447	448	563	637	672	677	752
Total Assets	1,140	1,259	1,459	1,488	1,625	1,806	1,943	2,254	2,335	2,459	2,710	2,912

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	127	171	153	148	104	239	210	162	165	221	310	200
	-89	-73	-144	20	-109	-85	-84	-147	4	-18	-199	-109
	-47	-97	0	-169	-0	-142	-126	-10	-180	-202	-92	-93
Net Cash Flow	-10	1	10	-2	-6	12	-1	5	-11	1	19	-2
Free Cash Flow	81	-135	129	112	62	235	151	36	54	151	220	40
CFO/OP	96%	100%	92%	96%	80%	109%	94%	98%	95%	96%	129%	81%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	25	24	28	26	28	34	30	19	25	22	18	24
Inventory Days	133	134	148	166	183	180	189	210	180	217	185	182
Days Payable	95	85	81	101	82	101	68	94	100	104	102	106
Cash Conversion Cycle	64	73	95	92	130	113	151	135	106	134	102	100
Working Capital Days	12	22	24	28	44	41	47	45	48	52	33	42
ROCE %	21%	22%	21%	19%	18%	22%	22%	15%	13%	18%	16%	15%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Sep 2023

Electral market share (Oral Rehydration Salts)
%

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx		xx.xx	xx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx		xx.xx	xx.xx
			xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
			xxx.xx	x,xxx.xx	xxx.xx	x,xxx.xx	x,xxx.xx
			xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx
x,xxx	x,xxx			x,xxx		x,xxx	x,xxx
				xx.xx	xx.xx	xx.xx	xx.xx
						x.xx	x.xx
x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Zifi market share (Cefixime)
%

API (Bulk Drugs) sales
INR crore

Domestic formulation sales
INR crore

Export formulation sales
INR crore

Field force (Medical Representatives)
count

Enerzal market share (Energy Drinks)
%

Per Capita Per Month (PCPM) productivity
INR lakhs per MR per month

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

3 Recently

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.65%	69.65%
	2.42%	2.43%	2.65%	2.51%	2.62%	2.67%	2.56%	2.41%	2.43%	2.32%	2.40%	1.40%
	8.12%	7.76%	6.94%	6.72%	6.02%	6.08%	6.37%	7.17%	6.81%	6.27%	6.29%	6.31%
	19.80%	20.15%	20.76%	21.11%	21.71%	21.60%	21.42%	20.76%	21.10%	21.76%	21.65%	22.63%
No. of Shareholders	56,928	55,341	52,377	50,634	55,400	55,228	53,880	54,445	54,157	53,788	52,730	55,045

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	68.89%	69.07%	69.07%	69.24%	69.35%	69.36%	69.49%	69.66%	69.66%	69.65%	69.65%
	9.99%	9.57%	8.86%	5.65%	5.71%	4.52%	3.80%	2.65%	2.56%	2.40%	1.40%
	3.97%	4.06%	5.25%	5.61%	4.02%	5.86%	8.27%	6.94%	6.37%	6.29%	6.31%
	17.16%	17.30%	16.82%	19.50%	20.92%	20.27%	18.44%	20.76%	21.42%	21.65%	22.63%
No. of Shareholders	25,651	26,403	27,674	26,217	40,329	86,503	57,012	52,377	53,880	52,730	55,045

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Concalls

Nov 2023
Transcript PPT REC
Feb 2023

Transcript

AI Summary
PPT
Nov 2022
Transcript
PPT
Nov 2022
Transcript PPT
Aug 2022
Transcript PPT
May 2022
Transcript PPT
Feb 2022
Transcript
PPT
Dec 2021
Transcript
PPT
Jun 2017

Transcript

AI Summary
PPT
Nov 2016

Transcript

AI Summary
PPT
May 2016

Transcript

AI Summary
PPT